The formed PLGA-ICG-R837 nanoparticles, which trigger photothermal ablation by a near-infrared laser, can produce tumor-associated antigens in vivo, while combined with CTLA4 antibody therapy, which can prevent recurrence after tumor elimination. The gene discussed is CTLA4; the disease is neoplasm.